Cited by 17Extracellular vesicles in diseaseNanoparticle-Based Drug DeliveryAlzheimer's disease research and treatments

Engineered Extracellular Vesicles/Exosomes as a New Tool against Neurodegenerative Diseases

Open access
Ferrantelli, Flavia, Chiozzini, Chiara, Leone, Patrizia, Manfredi, Francesco, Federico, Maurizio·2020·Pharmaceutics

Abstract

Neurodegenerative diseases are commonly generated by intracellular accumulation of misfolded/aggregated mutated proteins. These abnormal protein aggregates impair the functions of mitochondria and induce oxidative stress, thereby resulting in neuronal cell death. In turn, neuronal damage induces chronic inflammation and neurodegeneration. Thus, reducing/eliminating these abnormal protein aggregates is a priority for any anti-neurodegenerative therapeutic approach. Although several antibodies against mutated neuronal proteins have been already developed, how to efficiently deliver them inside the target cells remains an unmet issue. Extracellular vesicles/exosomes incorporating intrabodies against the pathogenic products would be a tool for innovative therapeutic approaches. In this review/perspective article, we identify and describe the major molecular targets associated with neurodegenerative diseases, as well as the antibodies already developed against them. Finally, we propose a novel targeting strategy based on the endogenous engineering of extracellular vesicles/exosomes constitutively released by cells of the central nervous system.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/pharmaceutics12060529

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Nefmut loaded into exosomes and fused with a single-chain fragment variable antibody at its C-terminus forms engineered exosomes, proposing a novel targeted strategy for neurodegenerative diseases.

    “The researchers loaded Nefmut into exosomes and fused a single-chain fragment variable antibody at its C-terminus to form engineered exosomes, which proposed a novel targeted strategy for endogenous engineering in the treatment of neurodegenerative diseases based on exosomes released by the cellular composition of the CNS [73].”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The citation lists haven’t been fetched yet

References 118 · Cited by 17

Research works printed but not linked: 1

  1. [63]Caron N.S. Wright G.E. Hayden M.R. Huntington Disease GeneReviews® Adam M.P. Ardinger H.H. Pagon R.A. Wallace S.E. Bean L.J. Stephens K. Amemiya A. University of Washington Seattle, WA, USA 1993 20301482

Authors
Ferrantelli, F., Chiozzini, C., Leone, P., Manfredi, F., & Federico, M.
Affiliations
Istituto Superiore di Sanità (IT)
Corresponding author
  • Ferrantelli, Flavia
  • Federico, Maurizio
Venue
Pharmaceutics
Publisher
MDPI AG
Published
2020-06-09
Volume
12
Issue
6
Pages
529
ISSN
1999-4923 (ISSN-L)
OpenAlex
W3034234364
Cited by
17
References
118
Citations by year
2026: 2 · 2025: 3 · 2024: 1 · 2023: 3 · 2022: 1 · 2021: 4 · 2020: 3
FWCI
0.26
Type
journal article
Language
en
Open access
Locations
  • Pharmaceutics (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
Ministero degli Affari Esteri e della Cooperazione Internazionale (PGR00810)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Extracellular vesicles in disease
  • Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
Keywords
engineered extracellular vesicles, exosomes, neurodegenerative diseases, intrabodies, protein aggregation, antibody delivery, central nervous system, oxidative stress, mitochondrial dysfunction, neuroinflammation, neuronal cell death

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review